Levosimendan

Also known as: (R)-Simendan, Simdax, Simda, OR-1259, [[4-[(4R)-1,4,5,6-Terahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazono]propanedinitrile, Mesoxalonitrile (-)-{p-[(R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl}hydrazone, ({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)malononitrile

Levosimendan (CAS 141505-33-1) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C14H12N6O and a molecular weight of 280.285 g/mol. Key properties include a melting point of 216-219ºC (dec.) and a density of 1.3±0.1 g/cm3. It is classified under GHS with signal word Warning and hazard statements H302 — Harmful if swallowed, H312 — Harmful in contact with skin and H332 — Harmful if inhaled. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 141505-33-1
Jingsj CID: J-17658-9
Molecular Formula: C₁₄H₁₂N₆O
Molecular Weight: 280.285 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	216-219ºC (dec.)
Density	1.3±0.1 g/cm3
Exact Mass	280.107269
PSA	113.43000
LogP	0.59
Refractive Index	1.673

GHS Safety & Compliance

IrritantSignal word: Warning

H302 — Harmful if swallowed
H312 — Harmful in contact with skin
H332 — Harmful if inhaled

Activity & Biological Data

Additional Information	[1]. Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245. [2]. Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7. [3]. Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46.

Additional Information

[1]. Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245. [2]. Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7. [3]. Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46.

Frequently Asked Questions

What is the CAS number of Levosimendan?

The CAS number of Levosimendan is 141505-33-1.

What are the molecular formula and molecular weight of Levosimendan?

Levosimendan has molecular formula C14H12N6O and molecular weight 280.285 g/mol.

Is Levosimendan hazardous?

Levosimendan has GHS signal word Warning and hazard statements H302 — Harmful if swallowed; H312 — Harmful in contact with skin; H332 — Harmful if inhaled.

What are the upstream and downstream products of Levosimendan?

For Levosimendan, Upstream Products: 6-(4-Aminophenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone, Malononitrile.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Levosimendan (CAS 141505-33-1)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-17658-9 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.